KLK6 blood levels in patients with intermediate-risk prostate cancer treated with definitive EBRT significantly decreased at 2 and 12 months following RT compared with the baseline levels before the initiation of RT, but not to undetectable levels.68 This evidence concerns the gene KLK6 and prostate cancer.